Irbesartan
- Generic Name
- Irbesartan
- Brand Names
- Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N6O
- CAS Number
- 138402-11-6
- Unique Ingredient Identifier
- J0E2756Z7N
- Background
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry co...
- Indication
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled ...
- Associated Conditions
- Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT03762850
- Locations
- 🇬🇧
Travere Investigational Site, London, United Kingdom
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 371
- Registration Number
- NCT03493685
- Locations
- 🇬🇧
Travere Investigational Site, York, United Kingdom
Bariatric Surgery and Pharmacokinetics of Irbesartan
- Conditions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03476603
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan
- Conditions
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2019-10-10
- Target Recruit Count
- 60
- Registration Number
- NCT03147677
- Locations
- 🇨🇳
Hunan Chenzhou NO.1 People's Hospital, Chenzhou, Hunan, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Hunan Yiyang Central Hospital, Yiyang, Hunan, China
A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Zhi-Hong Liu, M.D.
- Target Recruit Count
- 4
- Registration Number
- NCT02644486
- Locations
- 🇨🇳
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China
Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 61
- Registration Number
- NCT02597361
- Locations
- 🇫🇷
CHU DE BORDEAUX - Hopital Saint Andre, Bordeaux, France
🇫🇷CHU DE LYON - Hopital Femme Mere Enfant, Bron, France
🇫🇷CHU DE TOURS - Hopital Trousseau, Chambray-les-Tours, France
Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans
- Conditions
- Interventions
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 30
- Registration Number
- NCT02386293
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
Angiotensin II Antagonist in Severe Sepsis
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- University of Salerno
- Target Recruit Count
- 300
- Registration Number
- NCT01992796
- Locations
- 🇮🇹
Università di Salerno, Salerno, Italy
Drug Interaction Between Irbesartan and Hydrochlorothiazide
- Conditions
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Damanhour University
- Target Recruit Count
- 18
- Registration Number
- NCT01858610
- Locations
- 🇪🇬
Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01825850
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.